The Claim
Urolithin A administration in a mouse model of heart failure with preserved ejection fraction induced by high-fat diet and nitric oxide synthase inhibition is associated with improved diastolic function, reduced cardiac hypertrophy, and reduced cardiac fibrosis.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In mice with a specific type of heart failure caused by a high-fat diet and impaired nitric oxide production, Urolithin A treatment is linked to better heart relaxation, smaller heart muscle size, and less scar tissue in the heart.
See the scientific wording
Urolithin A administration in a mouse model of heart failure with preserved ejection fraction (HFpEF) induced by high-fat diet and nitric oxide synthase inhibition is associated with improved diastolic function, as evidenced by a reduction in the E/A ratio from elevated levels to near-normal values, alongside attenuation of cardiac hypertrophy and fibrosis, suggesting a potential role in mitigating structural and functional cardiac remodeling.
Urolithin A cleans up damaged energy factories in heart cells and lowers harmful fat molecules in the blood. This lets the heart muscle relax better, stops it from thickening abnormally, and prevents scar tissue from forming.
What the research says
1 studyIn mice with a type of heart failure where the heart can pump but doesn't relax well, giving them urolithin A helped their hearts relax better and reduced harmful thickening and scarring. It worked by cleaning up damaged energy factories in heart cells and lowering bad fats.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.